Digital Brand Media & Marketing Group, Inc. (OTCMKTS: DBMM) tripled on Thursday after the Company announced they are now compliant with FINRA Rule 6432 and have met the requirements under that rule to initiate a quotation for DBMM within four days of 10/26/2022. For Shareholders, this means the company has been approved to resume trading. Glendale Securities is the company’s sponsoring broker to FINRA and its designated Market Maker. The Form 211 clearance to resume trading has taken place. The removal of the OTC Market’s icon, CE follows the resumption as next step. In the interim, the market is cleared. This means US shareholders can buy and sell. The restriction for US buyers has been lifted.
DBMM is another short squeeze from Kramer and Asher of GTII fame which blew up from $0.50 to just under $9 per share in recent months as the shorts got taken to the cleaners. DBMM is an SEC filer and will have the skull & crossbones designation removed from OTCmarkets and be eligible for trading from the US within days. DBMM is also a revenue generating Company that continue to see significant growth reporting $164,000 in sales for the 3 months ended May 31, 2022 up from $120,000 for the same period last year.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Digital Brand Media & Marketing Group, Inc. (OTCMKTS: DBMM) operating out of NYC, New York and London, Uk operates through its wholly owned subsidiaries including Stylar Limited dba Digital Clarity. The Company is a multi-service digital marketing agency which specializes in creating effective strategies and campaigns for clients across a range of vertical markets, working in four key areas:
Search Engine Marketing – for search engines like Google, Yahoo Microsoft Bing
Analytics – measuring and analyzing web traffic to optimize performance.
Strategy & Consulting – digital transformation and marketing strategy.
Social Media – planning and measuring social metrics digitally in order to diagnose strategy.
DBMM Group can leverage its team’s experience in digital media and provide leading strategy, deployment and measurement to its core markets in many industry sectors, from creative to traditional corporate. The vertical B2B sectors encompass areas such as B2B ecommerce, SaaS, Blockchain, Fintech, Software Sales and Technology.
The Company is rolling out the services of both the technology and marketing services offerings from its operating base in the UK with a plan to increase its presence into the larger markets in the US. namely Los Angeles and New York. The intent in fiscal year 2022 will be a strategy of cash infusion to immediately correlate to increased revenues. Growth is clearly a function of available capital. Fiscal year 2021 reflected the Company’s continued progress by being awarded contracts for a number of new clients, in the midst of a very challenging year because of external factors beyond the Company’s control, specifically the pandemic and the SEC Matter awaiting the Commission’s final affirmation of the dismissal. The contract model strategy results in a full digital technology and marketing consultancy from design following an analysis of the client’s analytics, then executing and stewarding the evolution of the model. The Company’s mantra is “ROI is our DNA,” the underlying focus for business development. According to the Company’s 10k filed on November 5, 2021 DBMM has 7 full-time employees as of August 31, 2021.
To Find out the inside Scoop on DBMM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On October 27 DBMM announced that on October 26, 2022 FINRA processed a Form 211 relating to the initiation of priced quotations of DBMM, which means that the submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and therefore has met the requirements under that rule to initiate a quotation for DBMM within four days of 10/26/2022. FINRA’s processing of a Form 211 in no way constitutes FINRA’s approval of the security, the issuer, or the issuer’s business and relates solely to the submitting broker-dealer’s obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security.”
For Shareholders, this means the company has been approved to resume trading. Glendale Securities is the company’s sponsoring broker to FINRA and its designated Market Maker. The Form 211 clearance to resume trading has taken place. The removal of the OTC Market’s icon, CE follows the resumption as next step. In the interim, the market is cleared.
This means US shareholders can buy and sell. The restriction for US buyers has been lifted. Shareholders are also advised to do their own Due Diligence and hence ignore nonsense, opinions, and misinformation. Read FINRA 6532 regulations yourselves and SEC 15c2-11. Compliance has been fulfilled. This action represents another step forward; resuming normal trading is resuming normal business. Another update will be issued in 2-3 days according to DBMM Management.
Currently trading at a $1.8 million market valuation DBMM has a ton of room for growth from here. As DBMM goes back to “pink current” and can be purchase by US investors and shorts begin to cover this entire situation could blow up into a whole new stratosphere. As stated DBMM is another short squeeze from Kramer and Asher of GTII fame which blew up from $0.50 to just under $9 per share in recent months as the shorts got taken to the cleaners. Speculators are looking for DBMM to follow a similar course as GTII.We will be updating on DBMM when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in DBMM either long or short and we have not been compensated for this article.
MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 – $2.5299, with more than 2.98M shares exchanging hands.
So why did MTC surge today ?
The failure of Silicon Valley Bank led to a sell-off in equities and a shift to safe-haven assets, such as US Treasuries and gold. Markets have calmed down somewhat, and the worst of the equity sell-off seems to be over. However, the market anticipates that the markets will be somewhat uneasy until a better understanding of inflation is reached and what the Federal Reserve will do next week.
To Find out the inside Scoop on MTC, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Despite most investors currently avoiding the banking sector, Wall Street sees potential opportunities, particularly in regional banks. The chaos in the market has created opportunities in the industry and several banking stocks are being punished just for being a banking stock. The collapse of Silicon Valley Bank was due to its specialisation in venture-capital financing, which made it vulnerable to the higher interest rate regime of the past 12 months.
For more on MTC Subscribe Right Now!
Therfore, today’s gains in MTC seems to be more a sympathy bounce considering the overall banking sector. Earlier in March, MMTEC, Inc. (Nasdaq: MTC) declared that it will relocate its operations from Beijing to the Hong Kong Special Administrative Region, effective March 6, 2023. The Company’s subsidiary, MM Future Technology Limited, which is a Hong Kong incorporated limited company, will assume all operations previously conducted by its subsidiary, Gujia (Beijing) Technology Co., Ltd. However, Gujia will continue to carry out specific technical research and development functions. Further, the Company, through its subsidiary HC Securities (HK) Limited, and other entities, will continue to invest its human resources in asset management and securities underwriting, and other related businesses, aiming to attract global funds to invest in the Chinese market and support China’s economic growth. The Company’s new operations headquarters is located at Room 2302, 23rd Floor, FWD Financial Center, 308 Des Voeux Road Central, Sheung Wan, Hong Kong.
We will be updating on MTC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MTC.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have no position in MTC and have not been compensated for this article.
Cazoo Group Ltd (NASDAQ: CZOO) last traded at $2.62, a gain of +0.6400 (+32.32%). More than 5M shares exchanged hands compared to an average daily volume of 228K shares. Considering that the 52 week high of CZOO is more than 65$, there seems to be a lot of room to the upside.
To Find out the inside Scoop on CZOO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Why did CZOO surge last week? Welcome to the Carvana of the UK!
Cazoo, a publicly traded company (NYSE: CZOO), was founded in 2018 by serial entrepreneur Alex Chesterman OBE. The company’s mission is to revolutionize the UK’s car buying and selling experience by offering consumers better selection, value, transparency, convenience, and peace of mind. Cazoo’s goal is to make the car buying or selling process as simple as purchasing any other product online. The company enables customers to buy, sell, or finance a car entirely online, with delivery or collection available in as little as 72 hours.
Recently, Cazoo Group Ltd, the UK’s leading online car retailer, updated its business performance and progress with the restructuring announced in January. The CEO, Alex Chesterman, expressed satisfaction with the progress made so far in 2023, despite the challenging economic environment. The company has taken swift and decisive management action to restructure the group, improve unit economics, and reduce fixed costs. The rightsizing of headcount and operational footprint is well underway, and the company expects to complete the restructuring before the end of Q1 2023. The company has seen significant improvement in its GPU, with retail GPU tracking at approximately £900, up from £600 in Q4 2022. Cazoo has sold over 100,000 cars entirely online in the UK in the three years since its launch. The company remains fully focused on driving higher profitability and has appointed Jonathan Dunkley as Chief Operating Officer. Cazoo’s cash reserves remain strong, and the company expects to achieve profitability without external funding until H2 2024. The company expects to end 2023 with over £100m of cash and cash equivalents on its balance sheet and sell 40,000-50,000 UK retail units in the current year.
For more on CZOO, Subscribe Right Now!
The online car market in the UK has been growing rapidly in recent years, driven by increasing consumer demand for convenience and transparency in the car buying process. Online car retailers such as Cazoo, Carzam, and Cinch have emerged as major players in the market, offering a wide selection of used cars for sale online with home delivery or pickup options. These companies use advanced technology to provide customers with a seamless buying experience, including virtual vehicle inspections, transparent pricing, and easy financing options. The COVID-19 pandemic has further accelerated the shift towards online car buying as consumers seek to avoid in-person interactions and dealerships adapt to new ways of doing business.
So if CZOO learns from Carvana’s mistake, there is little to no doubt that CZOO could be the talk of the town in days to come. We will be updating on CZOO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CZOO.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CZOO, either long or short, and we have not been compensated for this article
Shares of Ocean Biomedical (NASDAQ:OCEA) surged more than 100% on Thursday, following a talk by the company’s scientific co-founder, Dr. Jack A. Elias, at Brown University’s Legorreta Cancer Center. The preclinical-stage biotech, which went public on the NASDAQ on February 15, focuses on developing novel treatments for deadly diseases, including malaria, multiple cancers, and pulmonary fibrosis.
During the talk, Dr. Elias presented exciting details about potential therapies to suppress tumors in various cancers, focusing on the company’s work in understanding the role of the protein Chitinase 3-like-1 (CHI3LI) in the progression of lung cancer. He also discussed his discoveries on how certain monospecific and bispecific antibodies can be used as therapies to treat non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The company aims to expedite these findings into phase 1 trials.
To Find out the inside Scoop on OCEA, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
The excitement over this preliminary news stems from the large target groups for both diseases. According to Cancer.net statistics, NSCLC is the leading cause of cancer death and the second-most diagnosed cancer in the US, affecting around 236,740 people. GBM is the most common primary brain tumor in adults, with an average survival period of just 15 months and no cure.
The recent surge in Ocean Biomedical’s shares also comes on the heels of an announcement on February 28 that co-founder Dr. Jonathan Kurtis had been awarded a patent for the discovery of the third parasite target PfCDPK-5. This target has the potential to be used to halt the malaria parasite in various stages of its cycle, opening up new possibilities for treating this deadly disease.
Ocean Biomedical’s focus on developing novel treatments for deadly diseases and its recent exciting findings have generated significant investor interest. However, it is important to note that investing in preclinical-stage biotech companies carries a high level of risk. There is no guarantee that these discoveries will translate into effective treatments or that the company will receive regulatory approval.
For more on OCEA Subscribe Right Now!
Nevertheless, the positive developments from Ocean Biomedical are a significant milestone and hold great promise for patients suffering from deadly diseases such as cancer and malaria. If the company’s discoveries prove successful in further clinical trials, they could potentially generate significant revenue and transform the standard of care for these diseases. We will be updating on OCEA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OCEA.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in OCEA, either long or short, and we have not been compensated for this article